Stephen Basil Thomas - Jan 1, 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
Emily Pimblett, as Attorney-in-Fact
Stock symbol
CLYM
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 04:15 PM
Previous filing
Jun 27, 2024
Next filing
Mar 27, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Options Exercise +50.2K +48.3% 154K Jan 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLYM Restricted Stock Units Options Exercise $0 -50.2K -50% $0.00 50.2K Jan 1, 2025 Common Stock 50.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.